Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Posted
Rocket Pharmaceuticals, Inc is a biotechnology business based in the US. Rocket Pharmaceuticals shares (RCKT) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Active investors
Our top pick for
Building a portfolio
52-week range | USD$9.01 - USD$67.48 |
---|---|
50-day moving average | USD$56.66 |
200-day moving average | USD$39.5419 |
Wall St. target price | USD$72 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-1.853 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -18.63% |
Return on equity TTM | -50.88% |
Profit margin | 0% |
Book value | $4.381 |
Market capitalisation | USD$3.3 billion |
TTM: trailing 12 months
There are currently 8.2 million Rocket Pharmaceuticals shares held short by investors – that's known as Rocket Pharmaceuticals's "short interest". This figure is 1.3% down from 8.3 million last month.
There are a few different ways that this level of interest in shorting Rocket Pharmaceuticals shares can be evaluated.
Rocket Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Rocket Pharmaceuticals shares currently shorted divided by the average quantity of Rocket Pharmaceuticals shares traded daily (recently around 431338.14541623). Rocket Pharmaceuticals's SIR currently stands at 18.98. In other words for every 100,000 Rocket Pharmaceuticals shares traded daily on the market, roughly 18980 shares are currently held short.
However Rocket Pharmaceuticals's short interest can also be evaluated against the total number of Rocket Pharmaceuticals shares, or, against the total number of tradable Rocket Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rocket Pharmaceuticals's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Rocket Pharmaceuticals shares in existence, roughly 140 shares are currently held short) or 0.2021% of the tradable shares (for every 100,000 tradable Rocket Pharmaceuticals shares, roughly 202 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Rocket Pharmaceuticals.
Find out more about how you can short Rocket Pharmaceuticals stock.
We're not expecting Rocket Pharmaceuticals to pay a dividend over the next 12 months.
Rocket Pharmaceuticals's shares were split on a 1:4 basis on 5 January 2018. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rocket Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Rocket Pharmaceuticals shares which in turn could have impacted Rocket Pharmaceuticals's share price.
Over the last 12 months, Rocket Pharmaceuticals's shares have ranged in value from as little as $9.01 up to $67.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rocket Pharmaceuticals's is 1.6876. This would suggest that Rocket Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction, and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. It also has additional infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.